ALZA'S NEW CHIEF WILL BE EX-GLAXO CEO ERNEST MARIO effective Aug. 2, the Palo Alto, Calif.-based drug delivery firm announced on July 12. Mario, deputy chairman and CEO of Glaxo Holdings until this spring, will succeed Martin Gerstel as co-chairman and CEO. Alza has been looking for a new chief executive since February 1992, when Gerstel announced his intention to leave the top spot to pursue personal interests. Mario, 55, left Glaxo in March over differences with the company's board of directors on what direction Glaxo should take in the OTC area ("The Tan Sheet" March 15, p. 3). Reportedly, Mario favored a more aggressive approach to building an OTC business than did others on the board. He joined Glaxo in 1986 as president of Glaxo U.S. and quickly rose to the top spot at the company. Prior to joining Glaxo, Mario was a group VP at Squibb. Mario will share the Alza chairmanship with founder Alejandro Zaffaroni. Jane Shaw will remain as president and chief operating officer, Alza said. Gerstel, 52, will assume the new title of vice chairman "for the interim to assist Dr. Mario during the transition," Alza added. After the transition, Gerstel "will continue as a member of the company's board of directors." Gerstel has been with Alza since its founding in 1968. Mario is assuming the top spot at Alza in the midst of the company's effort to expand its in-house promotional and manufacturing capabilities. Recent and upcoming launches of Alza- developed products include the Janssen fentanyl patch Duragesic, the Marion Merrell Dow nicotine patch Nicoderm and the two Ciba- Geigy OTC medicines -- Efidac/24 once-a-day pseudoephedrine and a 24-hour chlorpheniramine allergy product ("The Tan Sheet" July 12, In Brief). Alza also has recently established a spinoff to focus on developing proprietary drugs. Mario's main challenge, however, will be to maintain Alza's royalty stream, which remains reliant on sales of Pfizer's prescription antihypertensive Procardia XL. The $ 1 bil. product is now facing its first direct competition from a once-a-day nifedipine brand, Miles' Adalat CC. A third once-a-day nifedipine, Elan/Miles' Nifelan, is pending approval. A more significant threat could be a generic equivalent to Procardia XL. Alza's delivery system is patented through 2002, but generic firms, including KV, are understood to be pursuing bioequivalent versions. During Mario's tenure at Glaxo, Alza and Glaxo collaborated on the development of the sustained-release albuterol formulation Volmax, which was approved Dec. 23 after a five-year review. The prescription asthma drug was subsequently outlicensed to Muro. Alza and Glaxo have not disclosed any other collaborative agreements.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.
Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.
Center for Biologics Evaluation and Research Director Vinay Prasad said Commissioner Martin Makary wants to release previously inaccessible FDA documents, but previous commissioners have made the same pronouncements only to make little progress.
